Each name scored against its own layer of true peers. Commercial names score on full fundamentals; pre-revenue clinical names score on trend, analysts and roster only. A long-term entry tool, not a trading signal.
Our clinical read is anchored to Peter Mantas (gene-therapy and rare-disease specialist): catalyst-driven names like uniQure (Huntington's disease program) and ClearPoint Neuro, where the swing factor is FDA approval pathways rather than the science itself. The bigger story is the sector rotation, which now has a third independent angle: Jordi Visser frames Eli Lilly's weight-loss-drug cash flows as what finances the next generation of biology-focused AI — making healthcare an application of the AI boom, not a defensive hiding place. Healthcare remains the most under-owned major sector (its S&P weight fell from ~16% to ~8%) and the XLV healthcare fund is leading the market above its trend lines. The offset: rates staying higher hurts companies whose profits are years away, so for any pre-revenue clinical name, survival math — cash runway and share dilution — gates everything.
Every company is scored only against its true peer group on four axes — Value (price vs earnings), Quality (profitability, debt), Trend (price momentum), Analysts (Wall Street view). Green letters = strong vs peers, red = weak. SCREEN+ means top of its peer group and SCREEN− bottom — these are research rankings that flag where to look next, not buy or sell orders. Click any company row for a plain-English read.
| # | Name | Screen | Score | Axes V·Q·T·A | Roster | Price | Valuation | |
|---|---|---|---|---|---|---|---|---|
| 1 | IRWD | SCREEN+ | +0.91 | VQTA | · | $3.64 +0.3% | Fwd P/E 3× 5× EBITDA · +19% FCF · 2.7× sales |
⌄ |
Screen+ (top of cohort): cheap vs peers, average quality, on an attractive pullback, analysts cautious — top of its layer. Quality ROIC 30% ND/EBITDA 1.8 · Trend 200d +13% · 52w 63% · RS1y +200% · Analysts upside +32% · rating +0.27 | ||||||||
| 2 | CYTK | SCREEN+ | +0.58 | VQTA | · | $70.45 +1.7% | 20 mo runway · 10.0x cash $-402M net cash · +7% shares |
⌄ |
Screen+ (clinical): mid-trend. Catalyst-driven and binary, size small. Runway 20mo · EV/cash 10.0x · Dilution +7% · Analysts +42% | ||||||||
| 3 | INCY | SCREEN+ | +0.56 | VQTA | · | $107.96 +0.1% | Fwd P/E 12× 10× EBITDA · +7% FCF · 3.4× sales |
⌄ |
Screen+ (top of cohort): cheap vs peers, average quality, mid-trend, analysts cautious. Quality ROIC 20% ND/EBITDA -1.8 · Trend 200d +12% · 52w 94% · RS1y -3% · Analysts upside +2% · rating +0.48 | ||||||||
| 4 | IONS | SCREEN+ | +0.51 | VQTA | · | $73.84 +0.0% | 100 mo runway · 4.4x cash $+63M net cash · +7% shares |
⌄ |
Screen+ (clinical): on a pullback. Catalyst-driven and binary, size small. Runway 100mo · EV/cash 4.4x · Dilution +7% · Analysts +45% | ||||||||
| 5 | ALNY | SCREEN+ | +0.51 | VQTA | · | $286.61 -1.0% | Fwd P/E 27× 62× EBITDA · +2% FCF · 8.8× sales |
⌄ |
Screen+ (top of cohort): expensive vs peers, high quality, on an attractive pullback, analysts bullish. Quality ROIC 20% ND/EBITDA -0.7 · Trend 200d -24% · 52w 1% · RS1y -65% · Analysts upside +55% · rating +0.73 | ||||||||
| 6 | LLY | SCREEN− | -1.17 | VQTA | · | $1,149 -1.0% | Fwd P/E 26× 34× EBITDA · +1% FCF · 15.5× sales |
⌄ |
Screen− (bottom of cohort): expensive vs peers, average quality, extended or lagging. Quality ROIC 32% ND/EBITDA 1.1 · Trend 200d +20% · 52w 98% · RS1y -18% · Analysts upside +10% · rating +0.67 | ||||||||
| 7 | HIMS | SCREEN− | -1.90 | VQTA | · | $27.78 -3.8% | Fwd P/E 59× 71× EBITDA · +1% FCF · 3.0× sales |
⌄ |
Screen− (bottom of cohort): fairly valued, weak quality, on an attractive pullback, analysts cautious. Quality ROIC 1% ND/EBITDA 9.1 · Trend 200d -17% · 52w 26% · RS1y -111% · Analysts upside -3% · rating +0.35 | ||||||||
| # | Name | Screen | Score | Axes V·Q·T·A | Roster | Price | Valuation | |
|---|---|---|---|---|---|---|---|---|
| 1 | TEM | SCREEN+ | +1.48 | VQTA | · | $49.37 -0.5% | 38 mo runway · 11.5x cash $-61M net cash · +7% shares |
⌄ |
Screen+ (clinical): pipeline fairly priced, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 38mo · EV/cash 11.5x · Dilution +7% · Analysts +50% | ||||||||
| 2 | ILMN | SCREEN+ | +1.13 | VQTA | · | $162.19 -2.4% | Fwd P/E 27× 18× EBITDA · +4% FCF · 5.9× sales |
⌄ |
Screen+ (top of cohort): cheap vs peers, average quality, mid-trend, analysts cautious. Quality ROIC 14% ND/EBITDA 1.0 · Trend 200d +29% · 52w 90% · RS1y +25% · Analysts upside -7% · rating +0.42 | ||||||||
| 3 | GRAL | SCREEN+ | +0.71 | VQTA | · | $60.31 +0.2% | 36 mo runway · 1.6x cash $+806M net cash · +15% shares |
⌄ |
Screen+ (clinical): pipeline cheap vs peers, funding-stretched, mid-trend. Catalyst-driven and binary, size small. Runway 36mo · EV/cash 1.6x · Dilution +15% · Analysts +22% | ||||||||
| 4 | ISRG | SCREEN+ | +0.56 | VQTA | · | $405.92 -1.7% | Fwd P/E 34× 38× EBITDA · +2% FCF · 13.4× sales |
⌄ |
Screen+ (top of cohort): expensive vs peers, average quality, mid-trend. Quality ROIC 16% ND/EBITDA -0.5 · Trend 200d -17% · 52w 2% · RS1y -80% · Analysts upside +49% · rating +0.60 | ||||||||
| 5 | RGEN | -0.04 | VQTA | · | $133.50 +0.1% | Fwd P/E 52× 42× EBITDA · +1% FCF · 10.0× sales |
⌄ | |
Mid-cohort: expensive vs peers, average quality, mid-trend, analysts bullish. Quality ROIC 2% ND/EBITDA 0.6 · Trend 200d -3% · 52w 44% · RS1y -58% · Analysts upside +22% · rating +0.92 | ||||||||
| 6 | PSNL | -0.43 | VQTA | · | $9.63 +2.3% | 36 mo runway · 2.7x cash $+208M net cash · +51% shares |
⌄ | |
Mid-cohort (clinical): pipeline cheap vs peers, funding-stretched, mid-trend. Catalyst-driven and binary, size small. Runway 36mo · EV/cash 2.7x · Dilution +51% · Analysts +14% | ||||||||
| 7 | TWST | SCREEN− | -0.50 | VQTA | · | $76.44 +3.2% | 37 mo runway · 19.3x cash $+95M net cash · +3% shares |
⌄ |
Screen− (clinical): pipeline rich vs peers, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 37mo · EV/cash 19.3x · Dilution +3% · Analysts -11% | ||||||||
| 8 | AXGN | SCREEN− | -1.25 | VQTA | · | $42.00 -0.8% | 145 mo runway · 53.9x cash $+16M net cash · +4% shares |
⌄ |
Screen− (clinical): pipeline rich vs peers, well-funded, mid-trend. Catalyst-driven and binary, size small. Runway 145mo · EV/cash 53.9x · Dilution +4% · Analysts +12% | ||||||||
| 9 | TXG | SCREEN− | -1.65 | VQTA | · | $29.11 +0.2% | 1228× EBITDA +3% FCF · 5.1× sales |
⌄ |
Screen− (bottom of cohort): expensive vs peers, pre-revenue / unprofitable, mid-trend, analysts cautious. Quality ROIC -4% ND/EBITDA -153.7 · Trend 200d +55% · 52w 81% · RS1y +116% · Analysts upside -23% · rating +0.41 | ||||||||
| # | Name | Screen | Score | Axes V·Q·T·A | Roster | Price | Valuation | |
|---|---|---|---|---|---|---|---|---|
| 1 | CRBU | SCREEN+ | +1.50 | VQTA | · | $1.71 +3.0% | 15 mo runway · 0.3x cash $+112M net cash · +3% shares |
⌄ |
Screen+ (clinical): pipeline cheap vs peers, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 15mo · EV/cash 0.3x · Dilution +3% · Analysts +192% | ||||||||
| 2 | CRSP | SCREEN+ | +1.10 | VQTA | · | $50.96 +1.5% | 69 mo runway · 1.5x cash $+1581M net cash · +7% shares |
⌄ |
Screen+ (clinical): pipeline fairly priced, well-funded, mid-trend. Catalyst-driven and binary, size small. Runway 69mo · EV/cash 1.5x · Dilution +7% · Analysts +41% | ||||||||
| 3 | RPID | SCREEN+ | +0.89 | VQTA | · | $1.84 -2.1% | 14 mo runway · 1.8x cash $+14M net cash · +3% shares |
⌄ |
Screen+ (clinical): pipeline fairly priced, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 14mo · EV/cash 1.8x · Dilution +3% · Analysts +280% | ||||||||
| 4 | CRNX | SCREEN+ | +0.75 | VQTA | · | $33.98 +1.3% | 32 mo runway · 2.2x cash $+979M net cash · +16% shares |
⌄ |
Screen+ (clinical): pipeline fairly priced, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 32mo · EV/cash 2.2x · Dilution +16% · Analysts +153% | ||||||||
| 5 | GHRS | SCREEN+ | +0.52 | VQTA | · | $21.45 +3.8% | 77 mo runway · 3.7x cash $+280M net cash · +17% shares |
⌄ |
Screen+ (clinical): pipeline rich vs peers, well-funded, extended or lagging. Catalyst-driven and binary, size small. Runway 77mo · EV/cash 3.7x · Dilution +17% · Analysts +89% | ||||||||
| 6 | ABCL | +0.47 | VQTA | · | $5.31 +0.8% | 37 mo runway · 2.2x cash $+391M net cash · +1% shares |
⌄ | |
Mid-cohort (clinical): pipeline fairly priced, well-funded, mid-trend. Catalyst-driven and binary, size small. Runway 37mo · EV/cash 2.2x · Dilution +1% · Analysts +41% | ||||||||
| 7 | QURE | +0.35 | VQTA | · | $27.28 +1.7% | 42 mo runway · 2.4x cash $+86M net cash · +18% shares |
⌄ | |
Mid-cohort (clinical): pipeline fairly priced, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 42mo · EV/cash 2.4x · Dilution +18% · Analysts +31% | ||||||||
| 8 | NRIX | +0.11 | VQTA | · | $18.11 +6.7% | 27 mo runway · 1.7x cash $+537M net cash · +29% shares |
⌄ | |
Mid-cohort (clinical): pipeline fairly priced, funding-stretched, extended or lagging. Catalyst-driven and binary, size small. Runway 27mo · EV/cash 1.7x · Dilution +29% · Analysts +82% | ||||||||
| 9 | REPL | +0.07 | VQTA | · | $9.02 +4.6% | 29 mo runway · 0.7x cash $+408M net cash · +21% shares |
⌄ | |
Mid-cohort (clinical): pipeline cheap vs peers, adequately funded, extended or lagging. Catalyst-driven and binary, size small. Runway 29mo · EV/cash 0.7x · Dilution +21% · Analysts +55% | ||||||||
| 10 | RXRX | -0.12 | VQTA | · | $3.23 +2.7% | 24 mo runway · 1.1x cash $+665M net cash · +63% shares |
⌄ | |
Mid-cohort (clinical): pipeline cheap vs peers, funding-stretched, mid-trend. Catalyst-driven and binary, size small. Runway 24mo · EV/cash 1.1x · Dilution +63% · Analysts +155% | ||||||||
| 11 | SANA | -0.15 | VQTA | · | $2.79 +0.9% | 11 mo runway · 4.7x cash $+60M net cash · +10% shares |
⌄ | |
Mid-cohort (clinical): pipeline rich vs peers, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 11mo · EV/cash 4.7x · Dilution +10% · Analysts +210% | ||||||||
| 12 | BLLN <1yr | -0.24 | VQTA | · | $101.81 +2.2% | Fwd P/E 84× 114× EBITDA · +1% FCF · 12.2× sales |
⌄ | |
Mid-cohort: . Quality ROIC 5% ND/EBITDA -10.4 · Trend 200d +15% · 52w 57% · RS1y n/a <1yr-hist · Analysts upside +23% · rating +0.75 | ||||||||
| 13 | SMMT | SCREEN− | -1.54 | VQTA | · | $13.09 +0.0% | 26 mo runway · 17.5x cash $+514M net cash · +4% shares |
⌄ |
Screen− (clinical): pipeline rich vs peers, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 26mo · EV/cash 17.5x · Dilution +4% · Analysts +45% | ||||||||
| 14 | CLPT | SCREEN− | -1.59 | VQTA | · | $13.85 +0.0% | 23 mo runway · 8.8x cash $-12M net cash · +5% shares |
⌄ |
Screen− (clinical): pipeline rich vs peers, adequately funded, mid-trend. Catalyst-driven and binary, size small. Runway 23mo · EV/cash 8.8x · Dilution +5% · Analysts +16% | ||||||||
| 15 | CMPS | SCREEN− | -2.13 | VQTA | · | $12.19 +6.8% | 11 mo runway · 6.8x cash $+129M net cash · +39% shares |
⌄ |
Screen− (clinical): pipeline rich vs peers, funding-stretched, mid-trend. Catalyst-driven and binary, size small. Runway 11mo · EV/cash 6.8x · Dilution +39% · Analysts +52% | ||||||||
| # | Name | Screen | Score | Axes V·Q·T·A | Roster | Price | Valuation | |
|---|---|---|---|---|---|---|---|---|
| 1 | XBI ETF | +0.00 | VQTA | · | $134.46 +1.3% | ETF — price only | ⌄ | |
Price-only ETF (no fundamentals); on trend it is middling. Trend 200d +12% · 52w 93% · RS1y +0% | ||||||||
| 1 | ARKG ETF | +0.00 | VQTA | · | $34.08 +1.3% | ETF — price only | ⌄ | |
Price-only ETF (no fundamentals); on trend it is middling. Trend 200d +16% · 52w 83% · RS1y -15% | ||||||||